TrialPath
Multiple sclerosis · Miami

Multiple sclerosis clinical trials in Miami

6 recruiting multiple sclerosis studies within range of Miami. Click any trial for full eligibility criteria and contact info.

Longitudinal Cognitive Assessment by BoCA

NCT04114994 · Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia
Recruiting

The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.

Phase
TypeObservational
Age50 Years
WhereMiami, Florida, United States
SponsorAlzheimer's Light LLC
Tap for details
Apply

Study of COYA 302 for the Treatment of ALS

Recruiting

The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS). COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. It is comprised of low dose interleukin-2 (LD IL-2) and DRL\_AB (a biosimilar candidate for abatacept). Participants will be randomly assigned to receive one of 2 regimens of COYA 302 or placebo (an inactive substance) in a 1:1:1 ratio for 24 weeks in the double-blind (DB) period. Those who complete this part of the study will be eligible to receive one of the two regimens of COYA 302 for an additional 24 weeks in a blinded active extension phase (EXT). The study will assess changes in disease progression using established ALS clinical outcome measures, including the ALS Functional Rating Scale-Revised (ALSFRS-R), neurofilament (NfL), maximal inspiratory pressure (MIP), slow vital capacity (SVC), and neurological assessments. Additional objectives include evaluation of biomarkers and safety through routine clinical assessments and adverse event monitoring.

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WherePhoenix, Arizona, United States + 24 more
SponsorCoya Therapeutics
Tap for details
Apply

Clinical Applications of Advanced Ophthalmic Imaging

NCT03135327 · Multiple Sclerosis, Dry Eye Syndromes, Diabetic Retinopathy
Recruiting

The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls. There are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medical food (Ocufolin) for 6 months.

PhaseNA
TypeInterventional
Age18 Years – 99 Years
WhereMiami, Florida, United States
SponsorUniversity of Miami
Tap for details
Apply

TSC Biosample Repository and Natural History Database

NCT05676099 · Tuberous Sclerosis, Lymphangioleiomyomatosis
Recruiting

The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively.

Phase
TypeObservational
AgeAny
WhereBirmingham, Alabama, United States + 25 more
SponsorNational Tuberous Sclerosis Association
Tap for details
Apply

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Recruiting

The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

PhasePhase 3
TypeInterventional
Age18 Years – 65 Years
WhereBirmingham, Alabama, United States + 207 more
SponsorNovartis Pharmaceuticals
Tap for details
Apply

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Recruiting

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

Phase
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 87 more
SponsorTG Therapeutics, Inc.
Tap for details
Apply